J&J cuts price of lifesaving TB pill for some countries; cancer drug target takes on new glow

Taking stock of the drug industry, from the lab to the medicine chest

August 30, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

MARK RALSTON/AFP via Getty Images) STAT+ | J&J cuts the price of its lifesaving TB pill by more than half for many low- and middle-income countries Johnson & Johnson will cut the price of its life-saving TB pill by more than half for many low and middle-income countries. By Ed Silverman STAT+ | KRAS, the ideal cancer drug target that became 'undruggable,' takes on a new glow With the approval of Lumakras and Krazati, researchers are starting to gain ground in using a common genetic mutation to counter cancers. By Angus Chen and Bree Iskandar STAT+ | Workforce, capacity constraints slow ramp-up of new Alzheimer's drug Leqembi Hospitals say the backlog for Leqembi is temporary and reflects the challenge of building a treatment infrastructure for new drugs. By Robert Weisman — Boston Globe APStock Medicaid rebukes states for mistakenly disenrolling children Medicaid officials said they sent letters to all 50 states, ordering them to review their renewal process for the issue. By Sarah Owermohle

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser